利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.028 秒)

    Substituted sulfonamides
    3.
    发明申请
    Substituted sulfonamides 审中-公开
    取代磺酰胺

    公开(公告)号：US20070105914A1

    公开(公告)日：2007-05-10

    申请号：US10571842

    申请日：2004-09-14

    申请人： Helen Armstrong ,  Linda Chang ,  Ravindra Guthikonda ,  William Hagmann ,  Linus Lin ,  Shrenik Shah

    发明人： Helen Armstrong ,  Linda Chang ,  Ravindra Guthikonda ,  William Hagmann ,  Linus Lin ,  Shrenik Shah

    IPC分类号： A61K31/44 ,  A61K31/277 ,  A61K31/18

    CPC分类号： C07C311/06 ,  A61K31/18 ,  A61K31/277 ,  A61K31/44 ,  C07C311/03 ,  C07C311/13 ,  C07C311/16 ,  C07C311/17 ,  C07C311/19 ,  C07C311/29 ,  C07D209/08

    摘要： The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    摘要翻译： 本发明的取代磺酰胺是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。该化合物还可用于治疗药物滥用障碍，治疗肥胖或进食障碍，以及治疗哮喘， 便秘，慢性肠假性梗阻和肝硬化。

    Aralkyl amines as cannabinoid receptor modulators
    8.
    发明申请
    Aralkyl amines as cannabinoid receptor modulators 失效
    芳烷基胺作为大麻素受体调节剂

    公开(公告)号：US20070088058A1

    公开(公告)日：2007-04-19

    申请号：US10576381

    申请日：2004-10-27

    申请人： Shrenik Shah ,  Quang Truong ,  Hongbo Qi ,  William Hagmann

    发明人： Shrenik Shah ,  Quang Truong ,  Hongbo Qi ,  William Hagmann

    IPC分类号： A61K31/4412 ,  C07D249/08 ,  C07D213/63 ,  A61K31/415 ,  A61K31/277 ,  C07D231/12 ,  A61K31/4196

    CPC分类号： C07D213/74 ,  C07C255/58 ,  C07C317/28 ,  C07C317/48 ,  C07C323/63 ,  C07C2601/04 ,  C07C2601/14 ,  C07D207/32 ,  C07D207/325 ,  C07D213/38 ,  C07D213/57 ,  C07D213/61 ,  C07D213/64 ,  C07D231/12 ,  C07D231/38 ,  C07D239/26 ,  C07D249/06 ,  C07D249/08 ,  C07D249/14

    摘要： Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    摘要翻译： 结构式（I）的新型化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，可用于治疗，预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病，记忆缺陷，认知障碍，偏头痛，神经病，包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症，脑血管 事故和头部创伤，焦虑症，压力，癫痫，帕金森病，运动障碍和精神分裂症。 该化合物还可用于治疗药物滥用障碍，包括酒精和尼古丁成瘾，治疗肥胖或进食障碍，以及治疗哮喘，便秘，慢性肠假性梗阻和肝硬化。